QGE2 Stock Overview Offers sample to insight solutions that transform biological materials into molecular insights. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Qiagen Historical stock prices Current Share Price US$42.89 52 Week High US$44.05 52 Week Low US$36.63 Beta 0.37 1 Month Change 3.13% 3 Month Change 4.76% 1 Year Change 5.89% 3 Year Change -15.18% 5 Year Change 36.05% Change since IPO 53.09%
Recent News & Updates
QIAGEN Launches Ingenuity Pathway Analysis Interpret Dec 13
QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis Nov 28
Qiagen Collaborates with McGill University to Advance Microbiome Research Nov 13
Third quarter 2024 earnings released: EPS: US$0.44 (vs US$0.35 in 3Q 2023) Nov 08
Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024 Nov 07
QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics Nov 04 See more updates
QIAGEN Launches Ingenuity Pathway Analysis Interpret Dec 13
QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis Nov 28
Qiagen Collaborates with McGill University to Advance Microbiome Research Nov 13
Third quarter 2024 earnings released: EPS: US$0.44 (vs US$0.35 in 3Q 2023) Nov 08
Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024 Nov 07
QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics Nov 04
QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel to Improve Precision in Outpatient Respiratory Treatment Oct 29
QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications Oct 11
Qiagen N.V. to Report Q3, 2024 Results on Nov 06, 2024 Oct 10
QIAGEN N.V. Launches QIAcuityDx Digital PCR System for Clinical Testing in Oncology Oct 01
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform Sep 19
CFO, MD & Member of Management Board recently sold €677k worth of stock Sep 18
Qiagen N.V. to Report First Half, 2024 Results on Aug 16, 2024 Aug 09
Qiagen N.V. Updates Earnings Guidance for the Full Year 2024 Aug 02
Qiagen N.V. to Report Q2, 2024 Results on Jul 31, 2024 Jul 04
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System Jun 09 Qiagen to Discontinue NeuMoDx Integrated PCR Testing System
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care Jun 05
Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine May 30
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret May 16
Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results May 15
Qiagen N.V., Annual General Meeting, Jun 21, 2024 May 12
QIAGEN Announces the Availability of QCI Secondary Analysis May 03
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024 Apr 30
First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.39 in 1Q 2023) Apr 30
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use Apr 26
Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024 Apr 10
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024 Apr 04
Full year 2023 earnings released: EPS: US$1.53 (vs US$2.61 in FY 2022) Mar 12
Full year 2023 earnings released: EPS: US$1.53 (vs US$2.61 in FY 2022) Feb 10
Qiagen N.V. Provides Earnings Guidance for Year 2024 Feb 07
Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024 Jan 12
Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems Jan 08
QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation Nov 17
QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers Nov 12
Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research Nov 08
Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023 Nov 02
Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 3Q 2022) Oct 31
Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023 Oct 10
QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus Oct 06 QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness
QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits Sep 26
CFO, MD & Member of Management Board recently sold €1.2m worth of stock Sep 01
Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.42 in 2Q 2022) Aug 09 Qiagen N.V. Revises Earnings Guidance for the Full Year 2023
Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023 Jul 25
Now 20% undervalued after recent price drop Jun 19
QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening Jun 16
Qiagen N.V. Provides Earnings Guidance for the Year 2023 Jun 14
Now 20% undervalued after recent price drop Jun 05
Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook May 05
Full year 2022 earnings released: EPS: US$2.53 (vs US$2.36 in FY 2021) May 03
Board Member recently sold €204k worth of stock Mar 23
Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021) Mar 14
Now 20% undervalued after recent price drop Feb 22
Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021) Feb 12
Qiagen N.V. Provides Sales Guidance for the Full Year 2023 Feb 08
Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division Jan 28 Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023
Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million. Jan 11
Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million. Jan 09
Now 20% undervalued Dec 17
QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer Dec 14
Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance Nov 22
Third quarter 2022 earnings released: EPS: US$0.36 (vs US$0.58 in 3Q 2021) Nov 10
Qiagen N.V. Revises Earnings Guidance for the Year 2022 Nov 08
Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022 Oct 22
Now 20% undervalued after recent price drop Sep 29
Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses Sep 16
QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency Aug 16
Second quarter 2022 earnings released: EPS: US$0.42 (vs US$0.53 in 2Q 2021) Jul 29
QIAGEN Adds New Biopharma Products to QIAcuity Digital PCR Portfolio and Launches Expert Custom Assay Design Service Jul 28
Qiagen N.V. Raises Earnings Guidance for the Full Year 2022 Jul 27
Qiagen N.V. to Report Q2, 2022 Results on Jul 27, 2022 Jul 08
Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member Jun 25
CFO, MD & Member of Management Board recently sold €1.4m worth of stock Jun 15
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels May 16 Qiagen N.V., Annual General Meeting, Jun 23, 2022
First quarter 2022 earnings released: EPS: US$0.68 (vs US$0.57 in 1Q 2021) Apr 29
Qiagen N.V. Revises Net Sales Guidance for the Full Year 2022 Apr 27 Qiagen N.V. to Report Q1, 2022 Results on Apr 27, 2022
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 17
Now 21% undervalued after recent price drop Feb 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 10
QIAGEN N.V. Provides Sales Guidance for the First Quarter and Full Year of 2022 Feb 10
QIAGEN N.V. Provides Net Sales Guidance for the Fiscal Year 2022 Feb 09
Qiagen N.V. Announces New Generation of Quantiferon TB Test Gains Chinese Approval and Renewed WHO Recommendation Feb 07
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products Jan 19
QIAGEN Expands QIAstat-Dx Syndromic Testing Menu and Announces Launch Plans for New QIAstat-Dx Rise Higher-Throughput Version Jan 12
Qiagen N.V. Expands Quantiferon Portfolio in the Fight Against TB Jan 07 Shareholder Returns QGE2 AT Life Sciences AT Market 7D -0.09% 1.4% 1.1% 1Y 5.9% -4.5% -1.1%
See full shareholder returns
Return vs Market: QGE2 exceeded the Austrian Market which returned -1.2% over the past year.
Price Volatility Is QGE2's price volatile compared to industry and market? QGE2 volatility QGE2 Average Weekly Movement 2.9% Life Sciences Industry Average Movement 6.9% Market Average Movement 3.8% 10% most volatile stocks in AT Market 6.2% 10% least volatile stocks in AT Market 2.2%
Stable Share Price: QGE2 has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: QGE2's weekly volatility (3%) has been stable over the past year.
About the Company Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Show more Qiagen N.V. Fundamentals Summary How do Qiagen's earnings and revenue compare to its market cap? QGE2 fundamental statistics Market cap €9.59b Earnings (TTM ) €89.13m Revenue (TTM ) €1.89b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) QGE2 income statement (TTM ) Revenue US$1.97b Cost of Revenue US$663.20m Gross Profit US$1.30b Other Expenses US$1.21b Earnings US$92.93m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.42 Gross Margin 66.27% Net Profit Margin 4.73% Debt/Equity Ratio 57.0%
How did QGE2 perform over the long term?
See historical performance and comparison Dividends
2.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 11:51 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Qiagen N.V. is covered by 63 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Daniel Owczarski Avondale Partners Catherine Ramsey Schulte Baird Carla Bänziger Bank Vontobel AG
Show 60 more analysts 
